Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|March 1, 2016
Synexus Acquires Research Across America
The addition of Research Across America's sites means that Synexus can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
Advertisement
Synexus has purchased Research Across America (RAA) for an undisclosed sum. RAA was founded in 1989 by Dr. Jeffrey Adelglass, and has grown from a single location to multiple dedicated research sites across the U.S. Its sites have conducted over 2,000 clinical trials.
Synexus already owns 25 research sites in 10 countries. The addition of RAA’s sites means that it can now offer extra capacity, particular U.S. market expertise and therapeutic experience.
“Synexus already has a strong international footprint. This latest acquisition is an important one for Synexus as it marks our entry into the US market, giving us truly global capability,” noted CEO Christophe Berthoux. “We spent a great deal of time considering an appropriate partner and selected Research Across America as it has a number of synergies with the Synexus model. In addition, by adding these sites to our network we have also gained expertise in areas, such as dermatology and generics, enabling us to further support our client base.”
Read the
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Where AI Governance in Clinical Development Falls Short
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5